202 related articles for article (PubMed ID: 34551773)
21. Molecular Detection of
Zou Y; Zhu K; Pang Y; Han J; Zhang X; Jiang Z; Huang Y; Gu W; Ji Y
J Clin Transl Hepatol; 2023 Nov; 11(6):1355-1367. PubMed ID: 37719957
[TBL] [Abstract][Full Text] [Related]
22. Mutually exclusive FGFR2, HER2, and KRAS gene amplifications in gastric cancer revealed by multicolour FISH.
Das K; Gunasegaran B; Tan IB; Deng N; Lim KH; Tan P
Cancer Lett; 2014 Oct; 353(2):167-75. PubMed ID: 25086186
[TBL] [Abstract][Full Text] [Related]
23. Deep Targeted Sequencing and Its Potential Implication for Cancer Therapy in Chinese Patients with Gastric Adenocarcinoma.
Yu P; Wang Y; Yu Y; Wang A; Huang L; Zhang Y; Liu W; Wu H; Yao M; Du YA; Cheng X
Oncologist; 2021 May; 26(5):e756-e768. PubMed ID: 33511732
[TBL] [Abstract][Full Text] [Related]
24. Mutational landscape of gastric cancer and clinical application of genomic profiling based on target next-generation sequencing.
Cai H; Jing C; Chang X; Ding D; Han T; Yang J; Lu Z; Hu X; Liu Z; Wang J; Shang L; Wu S; Meng P; Lin L; Zhao J; Nie M; Yin K
J Transl Med; 2019 Jun; 17(1):189. PubMed ID: 31164161
[TBL] [Abstract][Full Text] [Related]
25. Molecular detection and clinicopathological characteristics of advanced/recurrent biliary tract carcinomas harboring the FGFR2 rearrangements: a prospective observational study (PRELUDE Study).
Maruki Y; Morizane C; Arai Y; Ikeda M; Ueno M; Ioka T; Naganuma A; Furukawa M; Mizuno N; Uwagawa T; Takahara N; Kanai M; Asagi A; Shimizu S; Miyamoto A; Yukisawa S; Kadokura M; Kojima Y; Furuse J; Nakajima TE; Sudo K; Kobayashi N; Hama N; Yamanaka T; Shibata T; Okusaka T
J Gastroenterol; 2021 Mar; 56(3):250-260. PubMed ID: 33106918
[TBL] [Abstract][Full Text] [Related]
26.
Carter JH; Cottrell CE; McNulty SN; Vigh-Conrad KA; Lamp S; Heusel JW; Duncavage EJ
Cold Spring Harb Mol Case Stud; 2017 Nov; 3(6):. PubMed ID: 28835367
[No Abstract] [Full Text] [Related]
27. FGFR2 Promotes Gastric Cancer Progression by Inhibiting the Expression of Thrombospondin4 via PI3K-Akt-Mtor Pathway.
Huang T; Liu D; Wang Y; Li P; Sun L; Xiong H; Dai Y; Zou M; Yuan X; Qiu H
Cell Physiol Biochem; 2018; 50(4):1332-1345. PubMed ID: 30355943
[TBL] [Abstract][Full Text] [Related]
28. Investigating FGFR2 gene as a blood-based epigenetic biomarker in gastric cancer.
Aleyasin SA; Moradi A; Abolhasani N; Abdollahi M
Mol Biol Rep; 2024 Feb; 51(1):253. PubMed ID: 38302798
[TBL] [Abstract][Full Text] [Related]
29. Identification of early genetic changes in well-differentiated intramucosal gastric carcinoma by target deep sequencing.
Yoshida T; Yamaguchi T; Maekawa S; Takano S; Kuno T; Tanaka K; Iwamoto F; Tsukui Y; Kobayashi S; Asakawa Y; Shindo H; Fukasawa M; Nakayama Y; Inoue T; Uetake T; Ohtaka M; Sato T; Mochizuki K; Enomoto N
Gastric Cancer; 2019 Jul; 22(4):742-750. PubMed ID: 30756200
[TBL] [Abstract][Full Text] [Related]
30. Evaluation of Fibroblast Growth Factor Receptor 2 Expression, Heterogeneity and Clinical Significance in Gastric Cancer.
Han N; Kim MA; Lee HS; Kim WH
Pathobiology; 2015; 82(6):269-79. PubMed ID: 26516773
[TBL] [Abstract][Full Text] [Related]
31. A randomized, open-label study of the efficacy and safety of AZD4547 monotherapy versus paclitaxel for the treatment of advanced gastric adenocarcinoma with FGFR2 polysomy or gene amplification.
Van Cutsem E; Bang YJ; Mansoor W; Petty RD; Chao Y; Cunningham D; Ferry DR; Smith NR; Frewer P; Ratnayake J; Stockman PK; Kilgour E; Landers D
Ann Oncol; 2017 Jun; 28(6):1316-1324. PubMed ID: 29177434
[TBL] [Abstract][Full Text] [Related]
32. Multiplex profiling of peritoneal metastases from gastric adenocarcinoma identified novel targets and molecular subtypes that predict treatment response.
Wang R; Song S; Harada K; Ghazanfari Amlashi F; Badgwell B; Pizzi MP; Xu Y; Zhao W; Dong X; Jin J; Wang Y; Scott A; Ma L; Huo L; Vicente D; Blum Murphy M; Shanbhag N; Tatlonghari G; Thomas I; Rogers J; Kobayashi M; Vykoukal J; Estrella JS; Roy-Chowdhuri S; Han G; Zhang S; Mao X; Song X; Zhang J; Gu J; Johnson RL; Calin GA; Peng G; Lee JS; Hanash SM; Futreal A; Wang Z; Wang L; Ajani JA
Gut; 2020 Jan; 69(1):18-31. PubMed ID: 31171626
[TBL] [Abstract][Full Text] [Related]
33. Prognostic impact of FGFR2/3 alterations in patients with biliary tract cancers receiving systemic chemotherapy: the BITCOIN study.
Rizzato M; Brignola S; Munari G; Gatti M; Dadduzio V; Borga C; Bergamo F; Pellino A; Angerilli V; Mescoli C; Guido M; Rearden J; Gringeri E; Cillo U; Dei Tos AP; Zagonel V; Loupakis F; Lonardi S; Fassan M
Eur J Cancer; 2022 May; 166():165-175. PubMed ID: 35303508
[TBL] [Abstract][Full Text] [Related]
34. Amplification of FGFR2 Gene in Patients with Advanced Gastric Cancer Receiving Chemotherapy: Prevalence and Prognostic Significance.
Shoji H; Yamada Y; Okita N; Takashima A; Honma Y; Iwasa S; Kato K; Hamaguchi T; Shimada Y
Anticancer Res; 2015 Sep; 35(9):5055-61. PubMed ID: 26254407
[TBL] [Abstract][Full Text] [Related]
35. Comprehensive Molecular Profiling of Intrahepatic and Extrahepatic Cholangiocarcinomas: Potential Targets for Intervention.
Lowery MA; Ptashkin R; Jordan E; Berger MF; Zehir A; Capanu M; Kemeny NE; O'Reilly EM; El-Dika I; Jarnagin WR; Harding JJ; D'Angelica MI; Cercek A; Hechtman JF; Solit DB; Schultz N; Hyman DM; Klimstra DS; Saltz LB; Abou-Alfa GK
Clin Cancer Res; 2018 Sep; 24(17):4154-4161. PubMed ID: 29848569
[No Abstract] [Full Text] [Related]
36. FGFR2 gene amplification in gastric cancer predicts sensitivity to the selective FGFR inhibitor AZD4547.
Xie L; Su X; Zhang L; Yin X; Tang L; Zhang X; Xu Y; Gao Z; Liu K; Zhou M; Gao B; Shen D; Zhang L; Ji J; Gavine PR; Zhang J; Kilgour E; Zhang X; Ji Q
Clin Cancer Res; 2013 May; 19(9):2572-83. PubMed ID: 23493349
[TBL] [Abstract][Full Text] [Related]
37. Cancer-related FGFR2 overexpression and gene amplification in Japanese patients with gastric cancer.
Minashi K; Yamada T; Hosaka H; Amagai K; Shimizu Y; Kiyozaki H; Sato M; Soeda A; Endo S; Ishida H; Kamoshida T; Sakai Y; Shitara K
Jpn J Clin Oncol; 2021 Oct; 51(10):1523-1533. PubMed ID: 34258618
[TBL] [Abstract][Full Text] [Related]
38. Multiple receptor tyrosine kinase activation attenuates therapeutic efficacy of the fibroblast growth factor receptor 2 inhibitor AZD4547 in FGFR2 amplified gastric cancer.
Chang J; Wang S; Zhang Z; Liu X; Wu Z; Geng R; Ge X; Dai C; Liu R; Zhang Q; Li W; Li J
Oncotarget; 2015 Feb; 6(4):2009-22. PubMed ID: 25576915
[TBL] [Abstract][Full Text] [Related]
39. Prospective analysis of the expression status of FGFR2 and HER2 in colorectal and gastric cancer populations: DS-Screen Study.
Yasui H; Takeno A; Hara H; Imamura H; Akamatsu H; Fujitani K; Nakane M; Kondoh CN; Yukisawa S; Nasu J; Miyata Y; Makiyama A; Ishida H; Yoshida N; Matsumura E; Ishigami M; Sugihara M; Ochiai A; Doi T
Int J Colorectal Dis; 2022 Jun; 37(6):1393-1402. PubMed ID: 35585358
[TBL] [Abstract][Full Text] [Related]
40. Identification of Potential Genomic Alterations Using Pan-Cancer Cell-Free DNA Next-Generation Sequencing in Patients With Gastric Cancer.
Kim B; Kim Y; Cho JY; Lee KA
Ann Lab Med; 2024 Mar; 44(2):164-173. PubMed ID: 37903652
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
